3OYW

Crystal structure of human galectin-1 in complex with thiodigalactoside


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.50 Å
  • R-Value Free: 0.245 
  • R-Value Work: 0.167 
  • R-Value Observed: 0.171 

wwPDB Validation   3D Report Full Report



Literature

Galectin inhibitory disaccharides promote tumour immunity in a breast cancer model

Stannard, K.A.Collins, P.M.Ito, K.Sullivan, E.M.Scott, S.A.Gabutero, E.Darren Grice, I.Low, P.Nilsson, U.J.Leffler, H.Blanchard, H.Ralph, S.J.

(2010) Cancer Lett 

  • DOI: 10.1016/j.canlet.2010.08.005
  • Primary Citation of Related Structures:  
    3OY8, 3OYW

  • PubMed Abstract: 
  • High level galectin-1 expression results in cancer cell evasion of the immune response, increased tumour survival and aggressive metastases. Using a galectin-1 polyclonal antibody, high levels of galectin-1 protein were shown to be expressed by breas ...

    High level galectin-1 expression results in cancer cell evasion of the immune response, increased tumour survival and aggressive metastases. Using a galectin-1 polyclonal antibody, high levels of galectin-1 protein were shown to be expressed by breast cancer cells established from FVB/N MMTV-c-neu mice as well as by the B16F10 melanoma cell line. In mixed lymphocyte cultures using tumour cells as antigenic stimulators, addition of recombinant galectin-1 dose-dependently inhibited lymphocyte production. Disaccharides were identified that inhibited galectin-1 function and increased growth and activation of CD8(+) CTL's killing cancer cells. X-ray crystallographic structures of human galectin-1 in complex with inhibitory disaccharides revealed their mode of binding. Combining galectin-blocking carbohydrates as adjuvants with vaccine immunotherapy in vivo to promote immune responses significantly decreased tumour progression and improved the outcomes for tumour challenged mice. This is the first report showing that suitably selected galectin-1 blocking disaccharides will act as adjuvants promoting vaccine stimulated immune responses against tumours in vivo.


    Organizational Affiliation

    School of Medical Science, Griffith University, Southport, QLD 4222, Australia. k.stannard@griffith.edu.au



Macromolecules
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 1
MoleculeChainsSequence LengthOrganismDetailsImage
Galectin-1A134Homo sapiensMutation(s): 0 
Gene Names: LGALS1
Find proteins for P09382 (Homo sapiens)
Explore P09382 
Go to UniProtKB:  P09382
NIH Common Fund Data Resources
PHAROS  P09382
Protein Feature View
Expand
  • Reference Sequence
Find similar proteins by:  (by identity cutoff)  |  Structure
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetailsImage
Galectin-1B134Homo sapiensMutation(s): 0 
Gene Names: LGALS1
Find proteins for P09382 (Homo sapiens)
Explore P09382 
Go to UniProtKB:  P09382
NIH Common Fund Data Resources
PHAROS  P09382
Protein Feature View
Expand
  • Reference Sequence
Oligosaccharides

Help

Entity ID: 3
MoleculeChainsChain Length2D Diagram Glycosylation3D Interactions
beta-D-galactopyranose-(1-1)-1-thio-beta-D-galactopyranose
E, F
2 N/A N/A Oligosaccharides Interaction
Small Molecules
Modified Residues  2 Unique
IDChainsTypeFormula2D DiagramParent
CME
Query on CME
AL-PEPTIDE LINKINGC5 H11 N O3 S2CYS
CSO
Query on CSO
AL-PEPTIDE LINKINGC3 H7 N O3 SCYS
External Ligand Annotations 
IDBinding Affinity (Sequence Identity %)
TDGKd :  78000   nM  PDBBind
TDGKd:  78000   nM  Binding MOAD
TDGKd:  24000   nM  BindingDB
TDGKd:  78000   nM  BindingDB
Biologically Interesting Molecules (External Reference) 1 Unique
Entity ID: 3
IDChainsNameType/Class2D Diagram3D Interactions
PRD_900027
Query on PRD_900027
E, FthiodigalactosideOligosaccharide /  Substrate analog

--

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.50 Å
  • R-Value Free: 0.245 
  • R-Value Work: 0.167 
  • R-Value Observed: 0.171 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 44.368α = 90
b = 58.367β = 90
c = 111.793γ = 90
Software Package:
Software NamePurpose
PROTEUM PLUSdata collection
REFMACrefinement
SAINTdata reduction
SCALAdata scaling

Structure Validation

View Full Validation Report



Entry History 

Deposition Data

Revision History 

  • Version 1.0: 2010-11-03
    Type: Initial release
  • Version 1.1: 2011-07-13
    Changes: Version format compliance
  • Version 1.2: 2017-11-08
    Changes: Refinement description
  • Version 2.0: 2020-07-29
    Type: Remediation
    Reason: Carbohydrate remediation
    Changes: Atomic model, Data collection, Derived calculations, Non-polymer description, Structure summary
  • Version 3.0: 2020-08-12
    Changes: Atomic model, Data collection, Derived calculations, Structure summary